TORONTO, Sept. 09, 2021 (GLOBE NEWSWIRE) — Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) (FRA: 1OA) (the “Company” or “Blueberries“), a Latin American licensed producer of medicinal cannabis and cannabis-derived products, announces the completion of a non-brokered private placement consisting of the sale of 20,813,817 common shares (“Common Shares”) at a price of C$0.10 per Common Share for aggregate gross proceeds of C$1,901,382 (or approximately US$1,500,000) (the “Offering”), of which 19,013,817 Common Shares was paid for in cash and 1,800,000 Common Shares was issued in connection for past services provided to the Company by an arm’s length third party service provider. Following the successful control of the Company’s SG&A over the past six months and improvements to operational standards in both cultivation and extraction of cannabis, the net proceeds from the sale of the Common Shares issued for cash consideration will be used to continue to: (i) implement the Company’s worldwide marketing strategy and ensuring the highest international quality standards in all of its operations; (ii) plant and equipment improvements, including the improvement to the Company’s state-of-art extraction pharma grade laboratory; (iii) obtaining GACP (Good Agricultural and Collection Practices) and EUGMP (European Union Good Manufacturing Practices) certifications; (iv) for new revenue streams; and (v) other general corporate and working capital purposes.

The Offering was led by Terraflos Inc. (“Terraflos”), a cannabis company with operations throughout Latin America that was founded, and is controlled, by Facundo Garreton, the Chairman, interim-CEO and a director of Blueberries. Terraflos recently announced the closing of its US$8 million seed round funding to continue developing and expanding its businesses in Latin America; in Uruguay through YVY Life Sciences, a company controlled by Terraflos, and in Colombia, through Blueberries. The seed funding round was led by FLA Ventures (“FLA”) (a current shareholder of Blueberries), MPE Investments and Yaax Capital. Terraflos is currently considering various opportunities in Argentina, Mexico and Brazil, and aims to expand its operations into those markets in the short term. In addition, Terraflos is preparing the launch of DrGea.com, a platform dedicated to the sale of cannabis products and the training of doctors specialized in the use of medicinal cannabis, dissemination and education of cannabis and its ecosystem, within the following weeks in Colombia, and expected to be scaled up throughout Latin America in 2021 and beyond. Terraflos also acquired a property in Garzón, Uruguay, where it expects to develop the first cannabis hub in the region focused on research and development as well as the promotion of the industry, tourism and training.

Facundo Garreton commented, “Terraflos is a company that promotes the development of a complete cannabis ecosystem, vertically integrating the different links of the cannabis production value chain and generating synergies between the various companies it controls. We are setting up the most relevant cannabis company in the region, mainly focused on the well-being of people, and to provide health solutions by delivering products that combine natural substances, science and technology while respecting nature and the environment.”

“We are pleased with Blueberries’ commercial operations moving from introductory sales of cuttings to associate growers, to solid sales of cannabis derivatives and extracts in Colombia and Peru. In addition, the company recently launched a high-quality tolling service to extract flowers and biomass for third party licensed producers that is positively impacting our revenue results and that is expected to help small and mid-size operators,” said Jose María Forero, the current President of Latin America operations of the Company.

New Director Appointment

The Company is also pleased to announce the appointment of Joaquin Barbera as a new independent member of the board of directors of the Company. Joaquín Barbera is the current CEO of the Broda Group, a company based in Argentina with more than 300 employees that invest and develop triple impact businesses from Mendoza Argentina to the World, whose drivers are innovation and sustainability. Joaquín studied business strategy at Harvard University and at the IAE Business School and he is a specialist in innovation and sustainability. He is a member of the board of Directors at Sistema B Argentina and represents Mendoza at the Union Industrial Argentina.

Early Warning Disclosure

Concurrent with the closing of the Offering, Terraflos also acquired in private transactions (the “Concurrent Transactions”): (i) 3,221,277 Common Shares and a previously issued convertible debenture of the Company (the “Debenture”) from Mr. Garreton (directly or indirectly through Glassford S.A., a company controlled by Mr. Garreton), and (ii) 9,800,000 Common Shares from FLA. The Debenture matures on July 16, 2022 and is convertible at a price equal to the lower of: (i) C$0.065, and (ii) the volume weighted average trading price of the Common Shares for 15 trading days prior to the conversion date, subject to a minimum conversion price of C$0.05.

Immediately prior to the Offering and the Concurrent Transactions, Mr. Garreton, directly and through Glassford S.A., owned 3,221,277 Common Shares as well as the Debenture. If the Debenture was converted in full at a price of $0.065 per share, it would result in the issuance of 14,416,762 Common Shares to Mr. Garreton for an aggregate holding on an as converted basis of 17,638,039 Common Shares, representing, on a partially diluted basis, approximately 10.28% of the outstanding Common Shares prior to the Offering.

Immediately following the Offering and the Concurrent Transactions, Mr. Garreton owned on an as converted basis (assuming conversion of the Debenture in full at C$0.065 per share), indirectly through Terraflos (which may be considered a joint actor of Mr. Garreton): 46,451,856 Common Shares representing, on a partially diluted basis, approximately 24.13% of the outstanding Common Shares prior to the Offering.

Mr. Garreton, through Terraflos, acquired the Common Shares and the Debenture referred to above for investment purposes, and he may, depending on market and other conditions, increase or decrease his beneficial ownership, control or direction over additional securities of the securities or otherwise. Other than as noted above and a right to a board seat for so long as Mr. Garreton holds at least 8% of the outstanding Common Shares on an as converted basis, Mr. Garreton does not have any plans related to any of the matters in the enumerated list in Item 5.1 of Form 62-103F1.

Mr. Garreton will prepare and file a report containing the information required by Form 62-103F1 – Required Disclosure under the Early Warning Requirements in connection with the matters referred to in this press release. Once filed, a copy of the early warning report will be available under the Company’s issuer profile on SEDAR at www.sedar.com.

MI 61-101 Disclosure

Participation by Terraflos in the Offering was considered a “related party transaction” pursuant to Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”). The Company was exempt from the requirements to obtain a formal valuation or minority shareholder approval in connection with Terraflos’ participation in the Offering in reliance of sections 5.5(a) and 5.7(1)(a) of MI 61-101. A material change report will be filed in connection with the participation of Terraflos in the Offering less than 21 days in advance of the closing of the Offering, which the Company deemed reasonable in the circumstances so as to be able to avail itself of potential financing opportunities and complete the Offering in an expeditious manner.

About Blueberries Medical Corp.

Blueberries is a Latin American licensed producer of naturally grown premium quality cannabis with its primary operations ideally located in the Bogotá Savannah of central Colombia. The Company is led by a specialized team with proprietary expertise in agriculture, genetics, extraction, medicine, pharmacology and marketing, Blueberries is fully licensed for the cultivation, production, domestic distribution, and international export of CBD and THC-based medical cannabis in Colombia. Blueberries’ combination of leading scientific expertise, agricultural advantages and distribution arrangements has positioned the Company to become a leading international supplier of naturally grown, processed, and standardized medicinal-grade cannabis oil extracts and related products.

About Blueberries

Additional information about the Company is available at www.blueberriesmed.com. For more information, please contact:

Jose Forero, President, Latin American Operations
[email protected]
Tel: +57 310 345 8808

Guillermo Rodriguez, CFO Blueberries Medical Corp.
[email protected]
Tel: +54 911 6015 2227

About Terraflos Inc.

Terraflos Inc. is a cannabis holding company, incorporated under the laws of the British Virgin Islands (BVI), with operations in both Uruguay and Colombia, through its investments in YVY Life Sciences and Blueberries, respectively. The company was founded and is led by Facundo Garreton, current chairman and interim-CEO of Blueberries.

Additional information about the company is available at www.terraflos.com. For more information, please contact:

Facundo Garreton, chairman and CEO.
[email protected]
Tel: +598 97 408 183

Cautionary Note Regarding Forward-Looking Information

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate, among other things, to: the use of proceeds from the Offering, expected synergies with Terraflos following the completion of the Offering, improvement to the Company’s state-of-art extraction pharma grade laboratory; obtaining GACP (Good Agricultural and Collection Practices) and EUGMP (European Union Good Manufacturing Practices) certifications; creation of new revenue streams and expected future revenue, commencement of commercial production of cannabis, CBD and other cannabis-derived products, successful implementation of full GMP standards at its extraction facility to allow for additional export potential to international markets, achieving additional milestones is contemplated, or at all, ability to expand distribution networks, ability to expand and upgrade the Company’s cultivation facilities in Colombia, internal expectations, expectations regarding the ability of the Company to access new Latin American and international markets, the ability to attract and retain new customers, and future expansion plans including development of the cultivation, production, industrialization and marketing of cannabis for commercial and scientific purposes.

These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the Colombian and international medical cannabis market and changing consumer habits; the ability of the Company to successfully achieve its business objectives; plans for expansion; political and social uncertainties; inability to obtain adequate insurance to cover risks and hazards; and the presence of laws and regulations that may impose restrictions on cultivation, production, distribution and sale of cannabis and cannabis related products in Colombia, Argentina and elsewhere; and employee relations. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

Additional information regarding the Company, and other risks and uncertainties relating to the Company’s business are contained under the heading “Risk Factors” in the Company’s Listing Statement dated January 31, 2019 and such other risk factors included in the management’s discussion and analysis of the Corporation for the year ended December 31, 2020, each filed on its issuer profile on SEDAR at www.sedar.com.

No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

CALGARY, AB, June 22, 2021 /PRNewswire/ – Decibel Cannabis Company Inc. (the “Company” or “Decibel”) (TSXV: DB) (OTCQB: DBCCF), a premium cannabis producer, is pleased to announce  the appointment of Paul Wilson as its Chief Executive Officer, effective Wednesday, June 23^rd.

Emphasizing the Company’s objective for brand growth, Mr. Wilson brings CEO and President level experience from some of Canada’s top consumer brands and is currently a member of Decibel’s board of directors. Mr. Wilson served as CEO, President, EVP, and Officer for consumer businesses, including leadership roles at Canadian Tire, Mark’s, Princess Auto, Spence Diamonds and Alcanna Nova Cannabis. As an experienced brand builder, Mr. Wilson has a consistent winning record in sectors ranging from hard goods to apparel and in formats ranging from start-ups and small chains to department stores and national chains.

“We are excited to continue our momentum with this key appointment. We were intent on adding a CEO who would complement our existing strategy and excellent management team” said Cody Church Chairman and interim CEO of Decibel. “The appointment follows a long and intensive search process that considered exceptional internal and external candidates. The focus of the search reflected the priorities of Decibel and the characteristics needed to address them. With Paul, we have selected a strategic leader and brand builder, with Decibel experience at the Board level.”

Paul Wilson commented “the Canadian cannabis industry is now coming together with the appropriate balance of resources to serve consumers. Decibel has done an exceptional job establishing premium brands like Qwest and Qwest Reserve, with production and supply capability to fulfill a significant segment of the rapidly evolving marketplace. I’m excited to be a part of this brand and this team, with a mandate to further strengthen and increase the value our shareholders have recognized.”

“I’d also like to thank the board of directors for its confidence and more importantly acknowledge the existing management team at Decibel who have established and grown our portfolio of brands as market leaders”, added Mr. Wilson.

About Decibel

Decibel is uncompromising in the process and craftsmanship needed to deliver the highest quality cannabis products and retail experiences. Decibel has three operating production houses along with its wholly owned retail business, Prairie Records. The Qwest Estate in Creston, BC is a licensed and operating 26,000 square foot cultivation, processing and distribution space which produces the widely championed, rare cultivar-focused brands Qwest and Qwest Reserve, which are sold in six provinces across Canada. The Thunderchild Cultivation Facility, is a licensed and operating 80,000 square foot indoor cultivation facility in Battleford, SK. The Plant, Decibel’s extraction, processing and manufacturing facility, in Calgary, AB has 15,000 square feet of Health Canada licensed extraction and product development space. This production house will fuel the growth of our brands Qwest, Qwest Reserve, and Blendcraft, into new and innovative product formats like concentrates, vapes, edibles and beyond.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statements

Forward Looking Information

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements.

In this news release, forward-looking statements relate to, among other things, the Company’s expectations regarding its ability to bring a significant pipeline of new and innovative products to the market, the Company’s ability to grow Qwest, Qwest Reserve and Blendcraft brands into new and innovative product formats, variations and its other business plans and expectations. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: risks relating to delays, regulatory changes and impacts, capital requirements, construction impacts, displacement requirements and unforeseen requirements resulting from the COVID-19 pandemic, the ability to obtain and maintain licences to retail cannabis products; review of the Company’s production facilities by Health Canada and maintenance of licences (including any amendments thereto) from Health Canada in respect thereof; future legislative and regulatory developments involving cannabis; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the labour market generally and the ability to access, hire and retain employees; general business, economic, competitive, political and social uncertainties; the satisfaction of conditions precedent under the Company’s credit facilities; timing and completion of construction and expansion of the Company’s production facilities and retail locations; and the delay or failure to receive board, regulatory or other approvals, including any approvals of the TSX Venture Exchange, as applicable. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, the Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

These forward-looking statements are made as of the date of this press release and the Company disclaims any intent or obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

SOURCE Decibel Cannabis Company Inc.

Related Links

https://decibelcc.com/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Widely hailed as Cannabis 2.0, the current phase of growth in the legal cannabis market is fueled by cannabis-derived products based on oils, distillates, and isolates. These extracts contain various active ingredients, or cannabinoids, like CBD, THC, and rare cannabinoids such as CBN, CBG and Delta-8 THC. You may have noticed the explosion of CBD products in health food, grocery, and even convenience stores. According to Grandview Research, the global CBD market was valued at $2.8 billion in 2020 and is expected to grow at a 21.2% CAGR over the next several years. It’s a vast opportunity in its infancy, and all of it depends on the extraction and processing of quality base ingredients from the cannabis plant.

Hempsana Inc. recognizes the opportunity and is moving quickly to become a major global player in the world of cannabis derivatives. The company has licenses and approvals in place both in Canada and in the European Union, an EU-GMP compliant extraction, production, and distribution facility, and several contracts already active. Helmed by a diverse and experienced executive team, Hempsana is poised to go public in the very near future and continues to expand its presence across the derivatives market.

Not Just CBD

After decades of effective prohibition on both the consumption of and research into the cannabis plant, the science of cannabis is starting to hit its stride. Over 100 cannabinoids have been identified, going far beyond the widely-known CBD and THC. There are many research studies and clinical trials of the potential benefits of cannabinoids, and scientists have identified a natural system in the human body that interacts with them called the endocannabinoid system. The US Food and Drug Administration went so far as to publish a brief encouraging and supporting cannabinoid research and drug development, a clear sign the science of cannabis has hit the mainstream.

How does all of this research and validation tie into Hempsana and its mission to be the most trusted name in cannabis derivatives? First, researchers and pharmaceutical companies certainly comprise a target market for Hempsana’s cannabinoid derivatives. They need something pure and clean to study, and Hempsana can provide. Second, the scientific momentum is fueling acceptance of the plant as a viable alternative to some more traditional products, widening Hempsana’s playing field. Perhaps most importantly, research has uncovered over 100 cannabinoids, each one with the potential to benefit people. Each of these compounds requires extraction and purification, giving Hempsana market opportunities far beyond the common CBD and THC array of products.

Click here to receive an investor presentation and corporate updates

To be clear, Hempsana is not ignoring CBD and THC but rather sees an opportunity to be an early mover with cannabinoids such as CBN and Delta-8 THC. In Hempsana’s native Canada, there are currently a couple of major players in the cannabis extraction world. Both MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) and The Valens Company (TSX: VLNS) (OTCQX: VLNCF) are mostly focused on THC and CBD extracts, and rightfully so. Hempsana firmly believes two things. One, the market growth and potential for the global THC and CBD products is very large and allows room for competitors. Two, there is tremendous value in developing lesser-known cannabinoid products.

Hempsana’s Story

Hempsana was founded in October 2018 in Toronto. The company received confirmation to extract CBD oil from industrial hemp in Hungary, EU in February 2019. This was quickly followed by a Health Canada Industrial Hemp License in August 2019, and the Health Canada Standard Processing License in May 2020 for its Canadian operations. Hempsana’s wholly owned 8,000 square foot EU GMP compliant facility located in Goderich, Canada, was fully completed and commissioned in Q4 2020, with commercial production launched in December 2020.

The Hungarian component is a key to future growth, providing entry into the lucrative EU market. The Canadian EU-GMP compliant facility was also built with international export capabilities in mind, as those requirements are generally considered the most stringent in the world. From a facility standpoint, the table was set in the first two years of Hempsana’s existence.

Since its inception, the company has executed a number of processing and offtake agreements, with current production of cannabinoid derivatives set for over 27,000 kg of biomass extraction.  Hempsana offers three basic types of ingredients: crude full-spectrum oil, full-spectrum high concentrate distillate, and active pharmaceutical ingredient (API) grade isolate. These ingredients form the foundation of products ranging from topical creams, to foods, to pharmaceutical drug candidates.

Hempsana sells ingredients wholesale to qualified buyers that formulate and manufacture their own products. The company also offers more comprehensive services that manage refinement, and include purification, remediation, and even formulation services to cannabis companies without those capabilities. Hempsana also offers white label services, partnering with clients to take products from the idea stage all the way to a ready-to-sell package.

What’s Next

Consider this all an introduction to a new player in the global cannabinoid derivatives market. Hempsana recently announced a business combination agreement that sets the stage for its near-term go-public event, which will introduce the company to new funding sources to help fuel its growth plans. Hempsana is currently in the process of partnering with national brands in Canada, EU, and Asia to create sales verticals in key growth areas including the health supplement, topical cream, vape, and edibles markets. It’s an exciting time for the people at Hempsana, and interested investors are encouraged to keep an eye on this space for further developments.

Click here to receive an investor presentation and corporate updates

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Robin Lefferts

The psychedelics  sector is quickly evolving into a multi-billion-dollar industry with a growing number of publicly traded companies. As with any new industry, there are many companies backed by little more than financiers looking to make a quick dollar before moving on to the next opportunity, which makes it important for investors to know who’s at the helm.

Let’s take a look at what sets Delic Holdings Inc.’s (CSE: DELC) (OTCQB: DELCF)

management team apart and why its board members represent a strong vote of confidence in the team and business over the long-term.

Experienced Management

Delic was founded by veterans from the cannabis industry—another highly-regulated industry that went from zero to billions of dollars in just a handful of years.

Co-Founders Matt and Jackee Stang were executives at High Times, a leading counterculture publication that became the voice for the cannabis industry. In fact, the monthly magazine had a circulation of over 500,000 copies an issue, rivaling Rolling Stone, and its website attracted 500,000 to five million users each month by 2014 as cannabis took off.

Matt Stang was a previous owner and operator of High Times, was instrumental in legalizing cannabis in multiple states and launched the Cannabis Cup in America. After interacting with all corners of the cannabis community for two decades, he helped found Delic two years ago as one of the first psychedelic corporations. His expertise in marketing, branding, business development and product viability and will prove invaluable as he shapes the company’s vision and path.

Most recently, John Coleman, Ph.D., former President of Anandia Labs, a cannabis biotech company focused on genetics and analytics, was hired as VP of Business Development. With a foot in both corporate and scientific worlds, Dr. Coleman is well-equipped to head up the company’s business development efforts as it looks to enter new vertical markets.

The company also recently hired Zak Garcia, former CMO of Bulletproof Inc., maker of the well-known Bulletproof® Coffee brand, as its Chief Marketing Officer. Mr. Garcia is a highly sought-after marketing and leadership strategist that helped grow Bulletproof® Coffee to over $250 million in revenue—experience that will help bring Delic to the next level of growth.

Click here to receive an investor presentation and corporate updates

Renowned Billion-Dollar Backers

Delic’s management team is supported by an impressive Board of Directors that reads like a who’s who of success stories in cannabis and other industries.

Paul Rosen was a co-founder of PharmaCan Capital Corp. and served as its first President and CEO.

Kraig Fox was a Senior Managing Director at Guggenheim Partners and later served as President and CEO of High Times. The involvement of these industry icons alone represents a big vote of confidence in the management team.

Mr. Rosen and Mr. Fox are joined by entrepreneur and venture capitalist Martin Tobias, finance veteran Sashko Despotovski and Dr. Markus Roggen, Founder and CEO of Complex Biotech Discovery Ventures. On the board of advisors, investors will find best-selling author Shep Gordon, Apollo Neuroscience Founder Dave Rabin and other leading voices.

The company’s well-known and respected board members provide a vote of confidence in the management team, valuable connections to grow its businesses and expertise that can be called upon to help make strategic decisions. With a wide range of expertise and disciplines, these team members could be invaluable in building long-term shareholder value.

Click here to receive an investor presentation and corporate updates

Looking Ahead

Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) is well-equipped to grow with its veteran executive team and its star-studded board of directors and advisors. With the right team in place, the company has been actively making acquisitions to become a strategic and diversified player in the nascent psychedelics industry today and well into the future. 

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Die Psychedelikaindustrie hat das Interesse von Pharmaunternehmen geweckt, die nach sichereren und effektiveren Produkten suchen, um ungedeckte medizinische Bedürfnisse im Bereich der psychischen Gesundheit zu befriedigen. Während psychedelische Moleküle vielversprechend sind, verlangen die Pharmahersteller, dass die Moleküle durch wissenschaftliche Techniken verbessert werden, um bestimmte therapeutische Ziele zu erreichen und Toxizitäten zu reduzieren.

Es gibt drei verschiedene Geschäftsmodelle, mit denen psychedelische Unternehmen diese vielversprechenden Medikamente entwickeln. Während die klinische Entwicklung von Medikamentenkandidaten das am häufigsten verwendete Modell ist, konzentrieren sich einige Unternehmen darauf, Moleküle zu entwickeln und dann die Lizenzen an andere Unternehmen zu vergeben. Wieder andere hoffen, den gesamten Prozess der Arzneimittelentwicklung zu umgehen, indem sie sich auf die weniger regulierten Märkte für Konsumgüter verlagern.

Werfen wir einen Blick auf aufkommende psychedelische Geschäftsmodelle und warum MagicMed Industries zu den am besten positionierten Unternehmen in diesem Bereich gehört.

Klicken Sie hier, um mehr über Investitionen in den Bereich der Psychedelika zu erfahren und Aktualisierungen über das Unternehmen zu erhalten

In der klinischen Entwicklung testen typische Pharmaunternehmen im Frühstadium Arzneimittelkandidaten in klinischen Studien mindestens der Phasen I und II. Wenn diese Unternehmen erfolgreich sind, versuchen sie häufig, mit einem größeren Pharmaunternehmen zusammenzuarbeiten, das über die Ressourcen und das Fachwissen verfügt, die erforderlich sind, um klinische Studien der Phase III zu verwalten und das Produkt letztendlich zu vermarkten.

# 1: Klinische Entwicklung

Vorteile

Hohe Margen: Arzneimittel sind in der Regel margenstarke Produkte, da sie Patentschutz genießen und häufig eher von Versicherungsunternehmen als von Einzelpersonen bezahlt werden.

Zugangsbarrieren: Arzneimittel weisen in der Regel hohe Marktzugangsbarrieren auf, da sie in der Regel patentgeschützt sind und die Durchführung klinischer Studien mit hohen Kosten verbunden ist. Insbesondere für die Psychedelika-Branche sind viele Unternehmen nicht in der Lage, einen starken Patentschutz für die von ihnen entwickelten Altmedikamente zu gewährleisten.

Große Märkte: Wenn ungedeckte medizinische Bedürfnisse erheblichen Profit versprechen, können die Marktchancen für Arzneimittel in Milliardenhöhe steigen.

Risiken

Hohe Kosten: Die Durchführung klinischer Studien kostet Millionen von Dollar und dauert Jahre, was häufig zu einer hohen Verdünnung und einem erhöhten Kapitalrisiko für das Unternehmen führt, das die Medikamente entwickelt.

Ausführungsrisiko: Die meisten klinischen Studienprogramme sind letztendlich erfolglos, was bedeutet, dass Pharmaunternehmen, die versuchen, nur einen einzigen Medikamentenkandidaten zu entwickeln, selbst oft erfolglos sind.

# 2: Erzeugung und Vergabe von Lizenzen neuer Moleküle

Einige Biotech-Unternehmen konzentrieren sich auf die Entdeckung und von Lizenzen von Arzneimitteln, um den Arzneimittelentwicklungsprozess für sich und ihre Partner zu beschleunigen. Basierend auf proprietären Methoden und Patenten synthetisieren und validieren diese Unternehmen neue Moleküle. Anschließend vergeben sie die Lizenzen der neuen Moleküle an Partnerunternehmen, die wiederum den Großteil der Entwicklungskosten und -risiken tragen. In der Psychedelikaindustrie werden die vorhandenen, bekannten Moleküle wie Psilocybin, MDMA, LSD und andere als Ausgangspunkt verwendet, von dem aus die neuen Moleküle durch Derivatisierung erzeugt werden.

Vorteile

Hohe Margen: Lizenzbasierte Geschäftsmodelle weisen hohe Margen auf, da nur bescheidene Investitionen für die Erstellung, Patentierung und Validierung erforderlich sind.

Vielfältig und skalierbar: Lizenzbasierte Geschäftsmodelle sind hoch skalierbar und äußerst vielfältig, da sie das Potenzial haben, mit mehreren Molekülen und Unternehmen sowie für verschiedene medizinische Indikationen zusammenzuarbeiten.

Risiken

Marketing: Lizenzbasierte Geschäftsmodelle können schwierig zu implementieren sein, da Lizenznehmer das meiste Ausführungsrisiko übernehmen.

# 3: Konsumgüter

Konsumgüterunternehmen konzentrieren sich darauf, kurzfristige Produkte auf den Markt zu bringen. Ohne die Notwendigkeit behördlicher Genehmigungen öffnen diese Produkte die Tür zu einer kurzfristigeren Kommerzialisierung als Geschäftsmodell für die klinische Entwicklung oder Lizenzierung. Einige Unternehmen entscheiden sich möglicherweise auch für unterstützende Gerichtsbarkeiten außerhalb der USA oder Kanadas.

Vorteile

Sofortige Einnahmen: Das Fehlen regulatorischer Anforderungen führt zu einer schnelleren Markteinführung und vermehrten Möglichkeiten für sofortige Einnahmen.

First-Mover-Vorteil: Frühförderer von Konsumgütern können früher ihre Marken entwickeln, die oft zu Marktführern werden.

Risiken

Geringere Barrieren: Konsumgüter sind normalerweise nicht durch Patente geschützt, was bedeutet, dass Wettbewerber leichter Zugang zum Markt haben.

Niedrigere Margen: Konsumgüter werden aufgrund des fehlenden Patentschutzes in der Regel für viel weniger Geld verkauft als zugelassene, regulierte Arzneimittel.

Kommerzialisierung: Konsumgüter können bei Erfolg schnell zu einer Ware werden, was die Gewinnmargen noch stärker unter Druck setzen kann.

Der einzigartige Ansatz von MagicMed

MagicMed Industries baut ein lizenzbasiertes Geschäftsmodell auf, um Partnern bei der Entwicklung einer breiten Palette von Psychedelika zu helfen, die auf bestimmte Anforderungen zugeschnitten sind.

Die Psybrary des Unternehmens ist eine Bibliothek neuer derivativer Moleküle, die darauf abzielt, Lizenzen an Dritte vergeben zu können, um patentierbare kommerzielle Produkte zu entwickeln. Diese Partner können sich gegenüber Konkurrenten mit vollständig patentierten und validierten Molekülen einen Vorteil verschaffen, um einzigartige pharmakologische Eigenschaften zu bieten, die für auf Ziele der Partner zugeschnitten sind.

Mit dem Ziel, bis Ende des Jahres erste Partner zu gewinnen, könnte MagicMed bereits Ende 2020 oder Anfang 2021 Einnahmen generieren. Weitere Einnahmen aus Meilensteinzahlungen beginnen im Jahr 2022, wenn die Partnerunternehmen klinische Studien durchführen. Das Unternehmen plant, Kunden Forschungskosten und Meilensteinzahlungen sowie langfristige Produktgebühren in Rechnung zu stellen, die den Weg für das Potenzial des blauen Himmels ebnen könnten.

Klicken Sie hier, um mehr über Investitionen in den Bereich Psychedelika zu erfahren und Aktualisierungen über das Unternehmen zu erhalten

Zusätzlich zu den pharmazeutischen Partnern wäre MagicMed gut positioniert, um sich 2022 in den Bereich der Konsumgüter auszuweiten, falls die behördliche Öffnung dies zulässt. Der Schritt könnte einer wachsenden Anzahl von Unternehmen für funktionelle Pilze helfen, patentierte Produkte zu entwickeln, um in einem Markt breit aufgestellt zu sein, der wahrscheinlich einen gewissen Grad an Kommerzialisierung erfahren wird.

Blick in die Zukunft

Es gibt viele verschiedene psychedelische Geschäftsmodelle, aber MagicMed Industries hat eines der vielversprechendsten übernommen – ein Lizenzmodell, das sich sowohl an pharmazeutische als auch an potenzielle Konsumgüterunternehmen richtet. Mit einem erfahrenen Managementteam an der Spitze ist das Unternehmen gut positioniert, um schnell hohe Margenumsätze zu erzielen.

Weitere Informationen finden Sie auf der Website des Unternehmens oder indem Sie die Investorenpräsentation herunterladen.

Haftungsausschluss

Der obige Artikel ist ein gesponserter Inhalt. CannabisFN.com und CFN Media wurden engagiert, um Bewusstsein zu schaffen. Bitte folgen Sie dem folgenden Link, um die vollständige Offenlegung unserer Vergütung einzusehen: http://www.cannabisfn.com/legal-disclaimer/

Dieser Artikel wurde von CFN Enterprises Inc. (OTCQB: CNFN) veröffentlicht, Eigentümer und Betreiber von CFN Media, der branchenweit führenden Agentur und dem Netzwerk für digitale Finanzmedien, die sich der aufstrebenden CBD- und legalen Cannabisindustrie widmen. Weitere Informationen erhalten Sie unter +1 (833) 420-CNFN.

Ryan Allway

Über Ryan Allway

Herr Allway verfügt über mehr als ein Jahrzehnt Erfahrung auf den Finanzmärkten als Privatinvestor und Finanzjournalist. Er ist seit der Gründung der Cannabisindustrie aktiv in ihr tätig und schreibt über öffentliche und private Unternehmen.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

May 29, 2020 — Santa Monica, CA — CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the leading media network dedicated to the global legal cannabis, CBD and psychedelics industries, today announces an article discussing Israel’s recent approval for cannabis exports and how companies like Isracann Biosciences, Inc. (CSE: IPOT) (OTC: ISCNF) are well-positioned to profit.

Israel gave final approval in mid-May for exports of medical cannabis, paving the way for more than one billion shekels ($273 million) in annual revenue. The country will become one of just three countries that have approved the export of medical cannabis to countries that permit its use—after Canada and the Netherlands— when the law goes into effect on June 13, 2020.

With its favorable climate and expertise in medical and agricultural technologies, Israel could become one of the world’s biggest producers of medical cannabis. iCAN estimates the global market for Israel’s medical cannabis could be as high as $33 billion, while Israeli companies like Syqe Medical have pioneered innovative medical cannabis technologies.

The go-ahead to export medical cannabis could open the door to new investment in the country, while existing Israeli producers, like Isracann Biosciences Inc. (CSE: IPOT) (OTC: ISCNF), could be well-positioned to benefit from near-term export demand.

Click Here To Receive Isracann’s Investor Presentation 

Let’s take a look at who stands to profit from the recent export decision and how investors can position themselves to capitalize on the developments.

Who Stands to Profit?

There are more than ten farms and five factories in Israel that meet the Health Ministry’s standards for medical cannabis exports, and several of them have already reached agreements to sell cannabis to Europe or Canada when licenses become available.

Isracann Biosciences Inc. (CSE: IPOT) (OTCQB: ISCNF) is Israel’s first pure-play cannabis firm wholly focused on becoming the nation’s premier, low-cost cannabis producer. The company has a joint venture agreement in place with a built 55,000 sq. ft. farm that’s expandable to 110,000 sq. ft. in the near-term and has access to over two million sq. ft. of private land.

“Our Hefer Valley farm is making great strides,” said Isracann’s VP of Operations, Matt Chatterton in a recent press release. “We engaged a specialist Israeli consultant to advance the certification of farm to EU-GMP standards thereby paving the way for our export distribution. In addition, the related post-harvest export facility is nearing readiness.”

In addition to its production, Isracann entered into a MOU earlier this year to distribute cannabis throughout European end markets. The distributor will import products through the Republic of Malta, subject to compliance and regulations, and is currently preparing a regional processing facility designed to meet EU-GMP standards.

Breath of Life International Ltd. planned to raise C$150 million on the Toronto Stock Exchange (TSE) through a public share offering priced at C$27 to C$32 per share last year, but management shelved plans for an IPO until market conditions improved in October 2019. The company reported $1.1 million in revenue during the first quarter of 2019 from the Israeli market.

Click here to view an exclusive interview with Isracann’s CEO Darryl Jones:

Click Here To Receive Isracann’s Investor Presentation 

Other Israeli cannabis producers that could benefit include:

• Cronos Group Inc. (TSX: CRON) has a strategic joint venture with Kibbutz Gan Shmuel, a commercial farming community, whereby it plans to build a 45,000 sq. ft. greenhouse in Israel that will help supply the European market.
• Aura Health Inc. CSE: BUZZ) holds convertible debt that converts to a 54% equity position in HolyCanna, a cultivation and nursery license in Israel. The company also signed a LOI with CannabiSendak to build a high-profile dispensary in Tel Aviv.
• Namaste Technologies Inc. (TSX-V: N) owns a 10% stake in Cannbit, a licensed cannabis operation in Israel. The company also has a collaboration and supply agreement with the company to purchase medical cannabis.

What’s Next for Israel?

Israel’s move to legalize medical cannabis exports could be transformative for many public and private companies operating in the country. Investors looking for exposure to the space may want to consider Isracann Biosciences Inc. (CSE: IPOT) (OTC: ISCNF) as one of the only pure-plays in the space or a handful of other companies that have exposure through joint ventures and investments.

Learn more about Isracann Biosciences by downloading their investor presentation or visiting their website.

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Cannabis investors had already been shifting from “unproven potential” to “profitability” over the past several quarters prior to the global health crisis. With the COVID-19 outbreak, investors have fled previous investments to profitable companies that aren’t reliant on costly or dilutive funding to sustain their operations.

THC BioMed Intl Ltd. (CSE: THC) recently recorded its second consecutive quarter of profitability along with more than $1 million in revenue. This represents profits of $88,191 for the three months ended January 31, 2020. Investors looking for exposure to the cannabis industry may want to take a closer look at the stock as an alternative to companies with high cash burn rates and losses in operations.

Click Here To Receive Updates on THC BioMed

Growing Revenue & Outlook

THC BioMed generated more than $1 million in revenue during the first two quarters of fiscal year 2020 with an average selling price of $4.20 per gram to medical patients and recreational buyers, including the Ontario Cannabis Store and BCcannabisonline. During the second quarter alone, revenue rose 163% year-over-year to $1,246,625.

“Over the last year, we have completed and started using new grow rooms to increase our output,” said President & CEO John Miller. “Our focus on high-quality, indoor-grown cannabis at reasonable prices has made our cannabis a best seller.”

The company achieved several key operational milestones over the past six months:

Sales of THC Kiss began on April 10, 2020. The cannabis beverage can be purchased by THC BioMed’s medical patients via the company’s online store.
Pure Cannabis Sticks — or filtered, paper cylinder pre-rolls — went into automated production.
A new three-year lease was signed for a property adjacent to the company’s production facility, which will be used to free up space for more production.
Its Cannabis Act license was amended to include the production and sale of cannabis edibles, topicals and extracts, opening the door to new markets.

Management believes that these operational milestones pave the way for revenue growth over the coming quarters. In particular, the launch of Cannabis 3.0 products will expand the company’s addressable market, while the production efficiencies offered by Pure Cannabis Sticks boost bottom line performance.

Click Here To Receive Updates on THC BioMed

Sustainable Profitability

THC BioMed reported net income of $88,191, gross profit before fair value adjustments of $759,959, and adjusted EBITDA of $131,549 during the second quarter, representing its second consecutive quarter of profitability—a rarity among licensed producers that have historically experienced a high cash burn rate.

Second quarter net income was lower than the $688,925 reported during the first quarter on the surface, but gross profit before fair value adjustments and adjusted EBITDA were higher than first quarter levels of $295,480 and $890, respectively. These figures suggest that the actual bottom line performance has improved quarter over quarter.

“We are proud to have achieved our second consecutive profitable quarter,” added Mr. Miller. “Our financial statements for Q2 2020 reflect the improvements we have realized in all key indicators of economic progress.”

It’s worth noting that the average price of $4.20 per gram is lower than the average prices reported for other licensed producers, which makes the profitability even more significant, as margins are lower than the competition. If industry average prices trend lower, the company doesn’t have to cut its prices in order to remain competitive.

Looking Ahead

THC BioMed Intl Ltd. (CSE: THC) is one of the few profitable licensed producers in the industry, giving them an edge over other companies that are reliant on potentially dilutive future fundraising to stay alive.

Click Here To Receive Updates on THC BioMed

Click here to read the full feature: https://bit.ly/2V2r0Se

THC BioMed Contact:
CEO: John Miller
[email protected]
844-842-6337

CFN Media Contact:

President Frank Lane
[email protected]
206-369-7050

About CFN Media
CFN Enterprises Inc. (OTCQB: CNFN) is the owner and operator of CFN Media, the leading agency and digital financial media network dedicated to the legal cannabis, CBD & Psychedelic industries.

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

What is the ideal setting for a brand to showcase its wares to the retail consumer? It is certainly not a crowded store with hundreds of brands competing for limited shelf space and consumer attention. Every brand out there would much rather have its own store, featuring its own product offerings, staffed by expert sales associates ready to educate consumers on the value of their products. In short, every brand would like its own version of the Apple Store or the Gap. Of course, every brand can’t afford to develop its own store, and cannabis licensing requirements often make the idea even more untenable.

CalEthos may have the answer for cannabis brands struggling to solve this problem. The company is currently financing the first of several planned cannabis superstores, appropriately called SHOWCASE, in Southern California. The concept is to provide partner cannabis brands their own space within a 20,000 sq. ft. SHOWCASE footprint, allowing them to fully display all that a brand has to offer. Each SHOWCASE location will also feature a medical pharmacy, an event center for community and consumer education, and a cafe and lounge areas to enhance the consumer experience and extend the shopper’s stay. Rather than the cramped, hurried environment common throughout retail cannabis, SHOWCASE promises to cater to both the customer and the brand in an elevated, inviting space.

CalEthos President Piers Cooper sat down with CFN Media to discuss the ideal setting for retailers to SHOWCASE their cannabis brand. Please click on the video below for the full story.

Click Here to Receive a CalEthos Investor Presentation & Company Updates

Click below to hear CalEthos’ President Piers Cooper discuss the SHOWCASE concept

CalEthos Did the Homework

The two executives largely responsible for the CalEthos concept, CEO Michael Campbell and President Piers Cooper, have a long history in advising, building, and investing in companies both private and public. They kept bumping up against the emerging cannabis industry and decided to investigate, looking for opportunities arising from shortcomings in the young marketplace. They settled on retail, visiting a wide variety of stores and brands and talking to everyone involved, from the consumer to the staff to the product companies.

These investigations highlighted the problems listed above, both for the brand and for the consumer. Cannabis has been legalized, but many stores still carry a bit of a black-market vibe which is uninviting to newer cannabis consumers. Space is at a premium, as most dispensaries don’t have the capital to build large format stores or expand and upgrade existing stores. Budtenders are generally helpful, but they are usually limited to some personal advice about a brand they like before making the sale and moving on to the next in line.

Click Here to Receive a CalEthos Investor Presentation & Company Updates

From the brand side, it is almost impossible to build a loyal customer base under such conditions. With advertising options limited, brands don’t have anywhere to turn. A given dispensary may carry 5 out of the brand’s 50 SKUs, whilst those 5 products are generally displayed amongst many other brands with limited space or capability for differentiation.

Campbell and Cooper came away from their research knowing there had to be a solution that provided a better consumer experience while enabling product makers to actively engage and educate those consumers.

Click below to hear CalEthos’ President Piers Cooper discuss The SHOWCASE Model Inspiration

The SHOWCASE Solution

CalEthos enlisted the help of Stephen Brady, the man responsible for the design of numerous Ralph Lauren, Bloomingdales, Gap, Old Navy, Banana Republic and other retail stores. Brady helped them realize the vision of an open, engaging, vital retail setting in which consumers are given space and options and educational opportunities. CalEthos is tuned in to the need to invite and educate ‘canna-curious’ consumers, and the SHOWCASE design enables that with event and education space along with lounge areas and a cafe. The concept is not turn and burn, though there is nothing stopping a customer from grabbing what they need and leaving quickly. Rather, the concept is explore and learn and enjoy. CalEthos believes consumers will gravitate to its model over the typical marijuana dispensary in the Southern California market.

Rendering of CalEthos SHOWCASE retail store

The company already knows that brands will appreciate the opportunity to create their own stores-within-a-store. Brand partners can procure dedicated space under the SHOWCASE Brand Membership Program that ranges from a 10’ x 16’ boutique with 90’ of shelf space, to shared kiosks in specialty product sections with 21’ of shelf space per brand, to 18’ of refrigerated shelf space in the Chill Zone for edibles and beverages. The SHOWCASE design also features a pharmacy dedicated to medicinal cannabis products and to provide advice for consumers exploring alternative medical options offered by cannabis products. All spaces are staffed by associates who are highly trained on products sold in their display areas.

Ready to SHOWCASE your Brand? Click Here to Apply.

Click below to hear CalEthos’ President Piers Cooper discuss the CalEthos Event Center

Overall, the concept is compelling and a refreshing change from the typical dispensary environment. Southern California, with its advanced legal market, huge population, and trend-setting reputation, is a prime location for the SHOWCASE concept. Investors interested in learning more about the opportunity are encouraged to follow the links. The future of cannabis retail awaits.

For Additional Information on CalEthos Please Visit the website at: https://www.calethos.com

CalEthos

CEO Michael Campbell

[email protected]

714-352-5315

CFN Enterprises

President Frank Lane

206-369-7050

[email protected]

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Robin Lefferts

Psychedelics are rapidly becoming both a mainstream treatment option and investment opportunity. With growing interest among researchers, forward-thinking companies are starting to build a presence in the space. 

In this article, we will take a look at the growing body of therapeutic evidence for psychedelics. How decriminalization is gaining ground, and how Ehave Inc. (OTC: EHVVF) along with other public companies are positioning themselves in the psychedelic space.

A Growing Body of Evidence

A growing body of evidence supports the use of psychedelics to treat a variety of different medical conditions. In 2016, Johns Hopkins researchers found that psilocybin produced a substantial and sustained decrease in depression and anxiety in cancer patients. A follow-up study on the same patients five years later found lasting effects from the one-time therapy.

The therapeutic evidence has become so overwhelming that Johns Hopkins established the Center for Psychedelic and Consciousness Research earlier this year to start rigorously investigating the drugs’ therapeutic potential. Researchers believe that it could have a beneficial impact on everything from smoking addiction to Alzheimer’s disease.

In addition to medical benefits, there’s plenty of anecdotal evidence that microdoses of psychedelics could improve mental health, well-being and productivity. Many prominent business leaders in Silicon Valley, including the late Steve Jobs, praised the benefits of microdosing psychedelics for creativity and cognition.

Click here to receive Ehave News and Investor Updates

Decriminalization Gain Ground

The growing interest among researchers has bolstered attempts by activists to decriminalize psychedelics throughout the country. Denver, Oakland and Santa Cruz have already decriminalized psychedelics over the past year, while California, Oregon and Iowa could see psychedelic-related measures on the ballot in November.

In the nation’s capital, Rep. Alexandria Ocasio-Cortez, D-NY recently introduced legislation that would allow researchers to more easily study the therapeutic and medicinal benefits of psilocybin and other psychedelics. These developments mirror what happened in the early medical cannabis industry where regulations were slowly relaxed over time.

It’s worth noting that these early efforts seek to decriminalize psychedelics and pave the way for research. Unlike the cannabis industry, there’s less interest in a recreational market and more interest in building a viable alternative therapy for countless different medical conditions that impact the brain—many without any current options.

Investors Start Taking Notice

Mind Medicine Inc. (NEO: MMED), better known as MindMed, became the first psychedelic pharmaceutical company to go public earlier this year on the NEO exchange. After raising $24.2 million in pre-public funding, the company plans to initially focus on addressing the opioid crisis and other forms of addiction with the use of psychedelics.

Click here to receive Ehave News and Investor Updates

Ehave Inc. (OTC: EHVVF) is another publicly-traded company in the space. Its Mycotopia Therapy subsidiary recently acquired PsychedeliTech and plans on hosting an inaugural PsyTech Summit in Tel Aviv, Israel on June 14-15, 2020. The conference will be modeled after the highly-successful CannaTech conference and connect key industry participants.

The company believes that it’s Dash platform will play a crucial role in the global advancement of psychedelic research. As a HIPAA and GDPR compliant platform, Dash is secure and compliant with some of the world’s strictest privacy laws. It’s an optimal way to compile psychedelic research and results to provide easy access for scientists globally.

Looking Ahead

Psychedelics are quickly picking up steam among both researchers and investors. As the market opens up, forward-thinking companies are building an early presence in the space before it grows into a large and mainstream industry. Cannabis investors may want to consider building a position in some of these companies given the similarities.

Please click here for additional Information on EHave, Inc. (OTC: EHVVF)

Please click here for additional Information on Mycotopia Therapy

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

The COVID-19 outbreak has become a major source of stress over the past several weeks. In addition to the fear and anxiety of disease, quarantines and “stay at home” orders have contributed to stress levels, leading to poor sleep, unhealthy eating, and other side-effects. It’s important for everyone to take inventory of their health and take action.

Let’s take a look at some strategies to cope with these heightened stress and anxiety levels, as well as how cannabidiol (CBD) and adaptogens could play a role.

How to Reduce Stress & Anxiety

There are many different ways to cope with the fear and anxiety stemming from the COVID-19 outbreak. While some people already have good routines in place, others may have to build new habits and integrate them into a completely new lifestyle under lockdown. The good news is that there’s plenty of good advice from the experts.

The Centers for Disease Control (CDC) had several recommendations:

• Take breaks from watching, reading, or listening to news stories, including social media.
• Eat a healthy, well-balanced diet, exercise regularly (away from others), try to get plenty of sleep and avoid smoking cigarettes, alcohol and drugs.
• Connect with others remotely using voice calls or video chats and discuss how you’re feeling and any concerns.
• Take time to yourself and try new activities that you might enjoy.

Other common suggestions include:

• Practice mindfulness by focusing on the present moment from time to time.
• Limit access to stressors by refusing non-essential tasks that are stressful and allowing yourself to take breaks.
• Delegate some responsibilities to others where possible, such as asking children to do the dishes.

While most people have experienced an impact from the crisis, those with pre-existing mental health conditions should be especially cognizant of worsening symptoms. Parents should also monitor the stress levels of children and teens that may experience more intense feelings. Call your healthcare provider if stress gets in the way of your daily activities for several days.

Accredited? Click here to see Innoviom’s deck and learn more about the company’s current offering

CBD & Adaptogens Could Help

There are many different foods and beverages that have a demonstrated ability to promote relaxation and reduced stress levels.

Most people are familiar with the benefits of green tea, chamomile, lavender and lemon balm when it comes to stress reduction. These ingredients are often referred to as adaptogens — or non-toxic plants that help the body resist physical, chemical or biological stressors. Many of them have been used for centuries in Chinese and Ayurvedic healing traditions.

Cannabidiol, or CBD, has also become a popular wellness product over the past several months. In early stage studies, researchers found that CBD may alter serotonin signals that modulate feelings of anxiety and depression. A generalized anxiety disorder study, for instance, showed that CBD reduced stress in animals, such as rats.

Accredited? Click here to see Innoviom’s deck and learn more about the company’s current offering

Innoviom’s goal is to bring these ingredients to consumers through functional beverages. It’s flagship Tranquini® brand is a natural de-stress drink that contains a unique blend of these relaxing adaptogens. Meanwhile, Wowie by Tranquini® combines these adaptogens with hemp extract to provide an even greater relaxation effect.

Unlike other companies, Innoviom has taken the research into adaptogens and CBD and turned it into great tasting functional drinks — with a focus on the great tasting part! Tranquini® is distributed through U.S. chains, such as Meijer, and via distributors, such as KeHE and UNFI. Wowie is also being rolled out in jurisdictions where sales are permitted.

Follow us on social media:

Looking Ahead

Innoviom is led by CEO Ahmed El Azizi, former Global VP of Functional Beverages at PepsiCo, who has over 20 years of beverage experience. He’s joined by Group CFO Christine Morcos, who came from Pfizer, Gillette and P&G and Chief Growth Officer Julia Trofimova, a former employee of several consumer product companies, including RedBull.

The company’s experienced consumer products team recognized an emerging market opportunity and has the ability to execute on an aggressive growth plan.

Accredited investors interested in learning more about investing in Innoviom can sign up to receive its investor deck and offering details.

Accredited? Click here to see Innoviom’s deck and learn more about the company’s current offering

Statements not evaluated by the FDA.

Innoviom, Inc. Company Contact:

Ahmed Al Azizi CEO

[email protected]

CFN Media Contact:

Frank Lane President

[email protected]

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.